BioSpace News Archive

AbCellera’s antibody discovery engine will isolate novel antibodies for the development of targeted CAR-T cell therapy

A class action, Dembrowski v. Bayer Inc., QBG 1611 of 2009, commenced in the Court of Queen’s Bench for Saskatchewan, was certified to advance claims regarding the combination oral contraceptives Yasmin® and Yaz® that Bayer marketed in Canada.

BIOLASE encourages fans to celebrate the partnership with #GameDayGrin social media sweepstakes

Proposed NRG-BN006 Phase 2/3 trial to begin enrollment in 2019

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, announced today the presentation of new data from the company’s Phase 2 study of TAVO™ (tavokinogene telseplasmid) for the treatment of metastatic melanoma.

Value of LATAM consideration has yielded tens of million appreciation over $193 million closing value

Telia Carrier announced that it has been selected again as a qualified supplier by The Quilt.

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018 at 8am Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Liht Cannabis Corp. (CSE: LIHT) (OTCQX: LIHTF) (FSE: 2M0) (“Liht”) or the “Company”) provides to its shareholders, a progress report on cultivation in North Las Vegas, Nevada.

Menarini Silicon Biosystems announced today that new data utilizing the company’s CELLSEARCH® Circulating Tumor Cell Test will be presented at the upcoming 2018 San Antonio Breast Cancer Symposium (SABCS).